ReviewAdvances in experimental medicine and biology2026
Genome Sequencing in Infectious Disease Outbreaks.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome sequencing has become a crucial tool in the management and understanding of infectious disease outbreaks. By decoding the entire genetic material of pathogens, this technology allows scientists to track the spread and evolution of infectious agents with unprecedented precision. During an outbreak, one of the key applications of genome sequencing is in tracing the transmission pathways of the disease. By comparing the genetic sequences of pathogens from different patients and sources, epidemiologists can determine the source of the outbreak and how the disease is spreading through populations. In addition, genome sequencing has the potential to identify mutations that may affect transmissibility, virulence, or resistance to treatment, providing critical insights for public health responses, for instance enabling targeted interventions, such as specific treatments or vaccines. During the last years, this was particularly evident for multiple internationally occurring severe outbreaks caused by either bacteria or virus, with special emphasis during the COVID-19 pandemic, where genome sequencing played a vital role in monitoring the emergence of new variants and informing vaccine strategies. As sequencing technologies continue to advance and associated costs decline, their integration into public health strategies will be essential for more effective control and prevention of infectious disease outbreaks in the future.
Indexed as
Identifiers
42071153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.